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Abstract 
 
 
Zebularine (1-(β-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one) was studied as both a 2’-
deoxyribosyl 5’-triphosphate derivative and as a template incorporated into an oligonucleotide.   
Using a novel Pyrosequencing assay zebularine acted as cytosine analog and was incorporated 
into DNA with a template pairing profile most similar to cytosine, pairing with greatest 
efficiency opposite guanine in the template strand. Guanine was incorporated with greater 
affinity than adenine opposite a zebularine in the template strand. Computer modeling of base-
pairing structures supported a better fit of zebularine opposite guanine than adenine. Zebularine 
acts as a cytosine analog, which supports its activity as an inhibitor of cytosine 
methyltransferase. 
 
 
 
 
Abbreviations: 
A: Adenine, C: Cytosine, G: Guanine, T: Thymine, dNTP: 2’-deoxynucleotide 5’-triphosphate,  
dZTP: 2'-deoxy-zebularine 5’triphosphate, ara-dCTP: 2'-deoxy-cytosine-β-arabinofuranoside 5’-
triphosphate, 5mdCTP: 5-methyl-2'-deoxycytidine 5'-triphosphate, dUTP: 2'-deoxyuridine 5'-
triphosphate 
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Introduction 
Methylation of cytosine at CpG dinucleotides is involved in gene silencing, and aberrations in 
DNA methylation are well described in cancer.  Aberrant de novo methylation in the regulatory 
sequences of tumor suppressor genes can result in their silencing and inappropriate gene 
regulation.  This abnormal DNA methylation may lead to abnormal cell growth and 
tumorigenesis(1).  Methylation of cytosine is catalyzed by DNA methyltransferase enzymes, all 
of which work through the same catalytic mechanism(2).  The addition of a methyl group at the 
5-position of cytosine is dependent on formation of a covalent intermediate between a conserved 
cysteine moiety of the enzyme and the 6-position of the cytosine ring (Figure 1A&B) (3-5).  
Numerous drugs have been shown to inhibit DNA methylation.  The most frequently studied 
agents are the cytosine analogs, 5-azacytidine and 5-aza-2'-deoxycytidine, which have a nitrogen 
at the 5-position of the pyrimidine ring (Figure 1C).  These triazine analogs are converted to their 
triphosphate forms by intracellular kinases and are then incorporated into DNA in place of 
cytosine.  Once incorporated into DNA, the methyltransferase enzyme attempts to catalyze 
methyl transfer by forming a covalent bond at the 6-position of the azacytosine ring that prevents 
DNA and cofactor release (6).  Thus these cytosine analogs covalently trap DNA 
methyltransferase during the methylation process.  Such covalent trapping leads to irreversible 
inhibition of the enzyme, depletion of the enzyme, and an overall decrease in DNA 
methylation(7, 8).   
 
Drugs that inhibit DNA methylation have demonstrated activity against cancer, especially 
hematologic malignancies(9, 10).  Both 5-azacytidine and 5-aza-2'-deoxycytidine are used to 
treat myeloid hematologic malignancies(11).  In vitro studies have shown that azacytidine 
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optimally inhibits DNA methylation in cell culture when given at low doses for prolonged 
periods of time, which allows for depletion of the enzyme with decreased cytotoxicity(8).  
Recent clinical studies have focused on the prolonged use of these drugs at low doses in order to 
maximize the ability to inhibit DNA methylation (12, 13).  Such studies have shown that these 
drugs may be more active at low doses with longer periods of administration (14).  Thus oral 
administration of a DNA methylation inhibitor may be ideal for clinical use. 
 
Another pyrimidine analog, zebularine, which can be orally administered, has also been shown to 
inhibit DNA methylation (Figure 1D) (15-18).  However, zebularine is approximately 30 times 
less potent in inhibiting DNA methylation when compared to 5-azacytidine and 300 times less 
potent than 5-aza-2'-deoxycytidine(15). Interestingly, once incorporated into DNA, the 2-(1H)-
pyrimidinone base of zebularine has an equivalent or greater potency compared to azacytosine in 
inhibiting DNA methyltransferase(19-22). Therefore, it is postulated that zebularine is a weaker 
inhibitor of DNA methylation due to a lower efficiency of incorporation into DNA compared to 
5-azacytidine and 5-aza-2'-deoxycytidine.  Prior to incorporation into DNA, zebularine must be 
converted to nucleotide precursors; zebularine is initially phosphorylated by uridine/cytidine 
kinase to a monophosphate and then further phosphorylated into a di- and triphosphate by 
cellular kinases.  In addition, conversion to a 2’-deoxyribonucleotide by ribonucleotide reductase 
is required in order for zebularine to be incorporated into DNA.  In contrast, 5-aza-2'-
deoxycytidine is already a 2’-deoxyribonucleoside that can be phosphorylated by deoxycytidine 
kinase, and is able to avoid the metabolic rate limiting step of reduction by ribonucleotide 
reductase(22, 23). 
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The ability of zebularine to inhibit DNA methylation is dependent on its capacity to efficiently 
incorporate in place of cytosine and act as a target for DNA methyltransferase.  This Trojan 
horse approach can lead to covalent trapping of the enzyme by the 2-(1H)-pyrimidinone ring of 
zebularine.  However, previous studies have shown that when zebularine is incorporated into the 
template strand of DNA, it acts as a poor cytosine analog and leads to blockage of DNA 
replication(24).  Therefore, we hypothesized that zebularine, as its 2’-deoxy-5’-triphosphate 
derivative, may not be efficiently incorporated into DNA in place of cytosine, given the lack of a 
4-amino group.  We used a novel pyrosequencing nucleotide extension assay and computer 
modeling to study the incorporation of zebularine and other nucleotide analogs opposite various 
nucleotide templates.  These studies were extended to examine incorporation of dNTPs opposite 
a template strand containing zebularine. 
 
Materials and Methods 
Primers and Templates 
All primers and templates except the zebularine-containing oligonucleotides were synthesized by 
the Microchemical Core Facility at the USC/Norris Comprehensive Cancer Center using an 
Applied Biosystems Inc, (ABI) 3948 DNA synthesizer (Templates) or ABI 394 DNA synthesizer 
(Complementary sequencing primer).  The template used for insertion analysis was a 30-
nucleotide oligomer based on the wild-type single stranded M13 bacteriophage DNA sequence 
from position 1797 to 1826 with the sequence 5'-
CTCAGTGTTACXGTACATGGGTTCCTATTG-3' (25), in which X denotes the variable 
position, which was A (M13A), C(M13C), G(M13G) , T (M13T), hypoxanthine (M13I) or 
zebularine (M13Z) in the respective oligomers.  The complementary primer used to conduct 
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pyrosequencing was an 18-mer with the sequence: 5'-CAATAGGAACCCATGTAC-3' 
(M13Comp1) (Figure 2). 
 
Zebularine-containing oligonucleotides were prepared using an Applied Biosystems 3400 DNA 
synthesizer. The corresponding 5'-O-DMT-2'-deoxyzebularine-3'-O-2-cyanoethyl-N,N-
diisopropylphosphoramidite (2'-zebularine phosphoramidite) was synthesised as reported (26). 
The oligonucleotide synthesis was performed in 3 parts: synthesis of the sequence to the 5' side 
of zebularine, addition of 2'-deoxyzebularine phosphoramidite (loaded at position 5 of the 
synthesizer), and finally synthesis of the remainder of the oligonucleotide sequence. This was 
done in order to use a special synthesis cycle for the addition of 2'-deoxyzebularine 
phosphoramidite, which required a longer coupling time. The standard bases were added using 
the standard LV200 synthesis cycle. Syntheses were performed without the removal of the last 
DMT group. 2'-Deoxyguanosine was protected with a dimethylformamidine group. Ammonia 
treatment was performed at 55ºC for 30 min to preserve the integrity of zebularine. 
Oligonucleotides were purified using reversed-phase HPLC (DMT on). The DMT was removed 
with 80% acetic acid and the acetic acid was removed by extraction with ethyl ether. The 
resulting product was desalted with Sephadex G-25 (NAP-10 column).  
 
 
Nucleotides 
dNTP substrates A, C, G, and T were purchased from Eppendorf  (Westbury, NY. catalogue 
#954143023). 2'-Deoxy-5-methylcytidine 5'-triphosphate (d5mCTP) was purchased from 
Fermentas (Hanover, MD #RO431), as was 2'-deoxyuridine 5'-triphosphate (dUTP, #R0133). 2'-
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Deoxy-cytosine -β-D-arabinofuranoside triphosphate (ara-dCTP) was purchased from Sigma (St. 
Louis, MO.  #C-3639). 2'-Deoxy-zebularine triphosphate (dZTP) was synthesized by Trilink 
Biotechnologies (San Diego, CA), as previously described (27).  Nucleotides were diluted from 
stocks to 10mM in PCR-grade water and a 1/10 serial dilution was performed to obtain the 1mM, 
0.1mM and 0.01mM working concentrations. 
 
Pyrosequencing 
Pyrosequencing is a novel method of DNA sequence analysis, offering an accurate and efficient 
alternative to previously described radiolabeling or fluorescence based methods (28).  
Incorporation of a dNTP into an oligonucleotide chain by DNA polymerase and the concomitant 
release of pyrophosphate (PPi) initiates a multi-enzyme pathway ultimately generating detectable 
light (29).  Light intensity is proportional to the quantity of dNTP incorporated during a constant 
time interval, and has been shown to be useful in quantitation of single nucleotide 
polymorphisms in mixed samples (30, 31).  Here we adapt the method to determine the efficacy 
of the polymerase in incorporating various conventional and modified nucleotide triphosphates 
opposite to a template of known base sequence by using a standardized concentration of dNTP 
substrate, template and primer.  We are able to extrapolate the Km and Km/Vmax for each dNTP 
by utilizing the signal intensity over a constant time interval as a surrogate for reaction velocity.  
 
Templates (M13A, M13C, M13G, M13T, M13I and M13Z) were combined individually with 
M13Comp1 to a final concentration of 0.25mM for each and aliquoted in triplicate to the assay 
plate.  Additionally an M13Comp1-only sample, as well as an M13G-only and a buffer-only 
control, were included to determine the signal obtained in the absence of template-specific 
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primer extension.  The conventional ‘A’, ‘C’, ‘G’ and ‘T’ nucleotide-dispensing cartridges of the 
pyrosequencer were filled with either 10mM, 1mM, 0.1mM or 0.01mM of the nucleotide being 
assayed for that run.   
 
Determination of Efficiency of Incorporation and Calculation of Km/V 
Chemoluminescent signal generated by pyrosequencing is converted to a numerical value 
referred to as a “Peak Height.”  This value is directly proportional to the amount of dNTP 
substrate incorporation in a constant time interval;  The peak height was used as a surrogate 
approximation of polymerase reaction velocity.   Pyrosequencing reactions were performed in a 
final volume of 12 microliters and the nucleotide dispensing tips were used to inject 50nl of 
dNTP in each reaction from which the final concentration of dNTP was calculated for each 
reaction.  The Km/V was estimated using a Lineweaver-Burke plot; where 1/[S (peak height)] 
was plotted against 1/[dNTP]. 
 
Computer Modeling 
Duplexes comprising the primer and template sequences and with a single base (Y) incorporated 
opposite X in the template were constructed in a B-DNA conformation (with part of the template 
strand as an overhang) using in-house software, NASDAC (32). Structures were built with X-Y 
= C-Z, A-Z, G-Z, I-Z, C-G, A-T, G-C and I-C, and for the zebularine-containing template with 
X-Y = Z-G, Z-C, Z-A and Z-T. Minimization of each structure was performed in AMBER8 (33): 
following neutralization with sodium ions, the structure was minimized for 4000 cycles, using a 
200Å non-bonded cutoff and a distance-dependent dielectric of 4r (using the parameter 
eedmeth=5). The AMBER parameters for zebularine were the same as those of cytosine, with 
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adjustment of charges and atom types around position 4 of the pyrimidine ring: charges for C4, 
H4, C5 and H5 (324, 99, -121 and 92 mE, respectively) were calculated using NEMESIS 
(version 1.1, Oxford Molecular) and adjusted to give the same total charge in the zebularine 
pyrimidine ring to that of cytosine; the AMBER atom types CA and HA were chosen for C4 and 
H4, respectively, and a few standard bond angle parameters (available on request) were added to 
accommodate these atom types in the pyrimidine ring.  
 
 
Results 
The optimal nucleotide concentration range was determined to be 0.01mM to 10mM dNTP for 
our pyrosequencing-based assay.  Concentrations higher than 10mM showed a plateau in signal 
(data not shown), with similar increases in control and experimental reactions, likely due to 
saturation of the system.  Concentrations below 0.01mM showed virtually no detectable signal 
above background.  Due to the nature of the enzymatic cascade, it is not possible to accurately 
assess the incorporation of dATP, as it can directly be used by the sulfurylase as an alternative 
substrate to ATP in generating the detected light signal (29).  No appreciable signal or titration 
was observed for the incorporation of any other dNTPs opposite the thymidine template (table 
1). 
 
Incorporation opposite Adenine  
dCTP did not show notable incorporation opposite adenine, as expected (Table 1).  Similarly, 
dZTP, despite lacking a 4-amino group, behaved like dCTP and showed no detectable 
incorporation opposite adenine. Likewise, dGTP showed no pairing with A.  dTTP, as expected, 
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was incorporated readily with a Km/Vmax =1.79x10-10 s-1 Incorporation of dUTP also occurred 
slightly less effectively (Km/Vmax =1x10-9 s-1).  Neither ara-dCTP nor d5mCTP showed notable 
incorporation.  
 
Incorporation opposite Cytosine   
Neither dCTP demonstrated significant incorporation opposite a cytosine template, as would be 
expected between homologous bases.  Conversely, a high titratable signal was obtained for the 
incorporation of dGTP opposite cytosine (Km/Vmax =3.14x10-10 s-1); the next base in the template 
strand is also a C, resulting in a higher signal for the incorporation of dGTP than the other 
favorable nucleotide pairings, due to a sequential extension by two bases rather than only one 
(refer to methods for template sequence).  No notable signal was obtained for the incorporation 
of any of the other standard and non-standard nucleotides against C in the template (Table 1).  
 
Incorporation opposite Guanine   
dCTP was incorporated opposite G (Km/Vmax= 1.48x10-10 s-1) similarly to the dNTPs in the other 
standard pairings (table 1). A similar, albeit slightly higher, signal was obtained for the 
incorporation of dZTP relative to dCTP (Km/Vmax =9.84x10-10 s-1 ), demonstrating that dZTP acts 
as a dCTP analog despite lacking the 4-amino group present on cytosine.  The extent of dZTP 
incorporation varied with the concentration of nucleotide injected.  The higher the concentration 
of dZTP used, the greater was the signal produced relative to dCTP (data not shown); as at 
concentrations <10mM,, dCTP produced a slightly higher signal, indicating that the slightly 
better utilization of dZTP as a substrate  based on a lower Km/Vmax  for dZTP, obtained herein, 
may vary depending on the dZTP concentration evaluated.   The pyrosequencer injects 0.5 
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microliters of dNTP solution into a 12 μl reaction volume, and therefore the approximate 
reaction concentrations of dZTP are 0.004mM, 0.04mM, 0.4mM and 4mM respectively.  
Previous estimates of intracellular dNTP pools range from 0.01mM to 0.213mM, and are within 
the range of our in vitro assay (34).  d5mCTP, which possesses a 4-amino group, was 
incorporated opposite guanine (Km/Vmax  =6.79x10-9 s-1 ) less effectively than the unmethylated 
form,  indicating some steric inhibition may exist; It is important to note that the 5 position of the 
pyrimidine ring is not involved in hydrogen bonding between G:C or A:T in Watson and Crick 
base pairing. Our assay also indicated that ara-dCTP is incorporated (Km/Vmax =1.99x10-10 s-1 ) 
less readily than dCTP (Table 1). 
 
Incorporation opposite Hypoxanthine 
dCTP appears to incorporate well opposite the guanine analogue hypoxanthine 
(Km/Vmax=1.18x10-10 s-1). However, dZTP was utilized less effectively (Km/Vmax=3.46x10-9 s-1) 
than either dCTP or d5mCTP; therefore, although dZTP is effective as a dCTP analog when 
incorporated opposite G, this does not appear to be the case for incorporation opposite 
hypoxanthine (HX).  This may be attributable to differences in hydrogen bonding between bases.  
A C:HX base pair is expected to form 2 hydrogen bonds, whereas a Z:HX pair can only form a 
single hydrogen bond, which may affect the stability of the base pair and the incorporation 
efficiency or rate of primer extension. d5mCTP was incorporated opposite hypoxanthine 
(Km/Vmax=5.28x10-9 s-1)  more readily than dZTP, but somewhat less effectively than dCTP 
opposite guanine (Table 1). 
 
Incorporation opposite Zebularine 
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Incorporation opposite Z was investigated by two methods.  As performed with the standard 
bases, individual dNTPs were incorporated opposite a Z-containing oligonucleotide template.  
As expected, dGTP incorporated opposite Z more readily than dCTP or dZTP (Table 1). dZTP 
also did not incorporate readily opposite Z (Km/Vmax=2.93x10-8 s-1).  We were unable to obtain 
data for dATP incorporation due to the high background generated by dATP injection into the 
Pyrosequencer at high concentrations. 
 
Incorporation of nucleotides opposite of Z was also studied using standard Pyrosequencing. The 
Pyrosequencer was programmed to treat the Z template site as a potential single nucleotide 
polymorphism and the relative incorporation of dTTP, dCTP, dGTP and dATP was measured. 
dGTP was most efficiently incorporated opposite a Z template, consistent with our previous 
results that Z acts as a C analog. Due to limitations of the method, these data should be viewed 
more qualitatively rather than quantitatively 
 
Although dGTP is favored to pair with Z, zebularine is not a perfect cytosine analog when in the 
template strand.  A significant decrease in signal was noted after dGTP incorporation opposite of 
Z, which reflects a termination of oligonucleotide extension.  In order to investigate this finding 
further, the standard oligonucleotide primer-template duplex was changed so Z was not the initial 
template base.  The complementary oligonucleotide used to hybridize with the template 
oligonucleotide was shortened to allow the incorporation of 6 bases prior to reaching the Z 
template target base.  In addition, the oligonucleotide allowed 11 bases to be incorporated after 
the Z template target base.  With incorporation of each nucleotide triphosphate there is a small 
(average 6.5%) decrease in signal intensity, showing that there is not 100% efficiency in 
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extending all oligonucleotides.  With incorporation of dGTP opposite Z there was a marked 
(53.2%) decrease in signal (data not shown).  Therefore G is the preferred partner of Z when Z is 
in the template strand, but this Z:G pairing is not as efficient as C:G and A:T pairing in 
permitting chain extension when Z is in the template strand.  This finding is unique to zebularine, 
since the identical experiment was performed with hypoxanthine in the template and no decrease 
in signal intensity was seen with dCTP incorporation opposite hypoxanthine (data not shown). 
 
Computer Modeling 
DNA structures formed after dZTP incorporation opposite cytosine, guanine, adenine and 
hypoxanthine are shown in Figure 3. As expected, two hydrogen bonds are present in the newly-
formed G-Z base pair (Figure 3A), and one hydrogen bond is present in the HX-Z base pair 
(Figure 3D). This is reflected in the AMBER8 energies for the DNA structures containing the G-
Z and HX-Z pairs (Table 2), which show the former structure to be more stable. Incorporation of 
dZTP opposite adenine (Figure 3B) results in a skewed conformation of the zebularine 
nucleotide, since no A-Z hydrogen bond formation can occur. Incorporation of dZTP opposite 
cytosine (Figure 3C) results in formation of a weak interaction between the cytosine 4-amino 
group and N3 of zebularine, but this requires twisting of dZTP and subsequent disruption of the 
developing duplex structure. Incorporation of dCTP opposite guanine (to give a normal Watson-
Crick G-C pair) resulted in a structure that was more stable than the structure containing the G-Z 
pair (Table 2). This suggests that something other than the energetics of the newly-formed base 
pair accounts for the increased incorporation of dZTP opposite guanine, compared to dCTP.  A 
similar behavior has been observed when other nucleoside analogs (35) and non-polar isosteres 
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of nucleobases (36) were incorporated into DNA, indicating that the geometry rather than 
thermodynamic stability is important for DNA polymerase activity. 
 
For zebularine-containing templates, incorporation of dGTP opposite Z is energetically 
favorable, compared to the other dNTPs (Table 2), which is consistent with the experimental data 
and is a result of the two hydrogen bonds formed in the Z-G base pair (Figure 4A). The energies 
for incorporation of dATP, dTTP and dCTP opposite Z are similar, but it is perhaps of note that a 
hydrogen bond forms in the Z-A and Z-T base pairs (Figure 4B and 4D, respectively). These 
interactions are between N3 of zebularine with the 6-amino group of adenine and N3-H of 
thymine respectively. Both require some skewing of the base pair, which may compromise 
further chain extension. In contrast, incorporation of dCTP opposite Z does not result in a 
hydrogen bond between the Z and C bases; the distance between zebularine N3 and the cytosine 
4-amino group (Figure 4C) is over 4 Å.  These data support and offer an explanation for the 
experimental data, which show that both dATP and dTTP can incorporate opposite Z with low 
efficiency, but dCTP cannot incorporate opposite Z. 
 
Discussion 
We have shown that zebularine is utilized more effectively as a substrate for incorporation into 
DNA as a cytosine analogue, than as a thymine analogue. Our data also show that zebularine 
shows a greater degree of incorporation than ara-dCTP opposite both guanine and hypoxanthine, 
and that, in comparison with cytosine, zebularine is utilized less readily for incorporation 
opposite hypoxanthine 
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The pyrosequencing assay has inherent limitations due to the use of the exonuclease-deficient 
Klenow fragment of Escherichia coli, which lacks the proofreading activity that would be 
present in an in vivo model, as well as the eukaryotic polymerase active in human cancer cells. 
However, previous studies have shown this to be a solid foundational model system to elucidate 
the basic mechanism of DNA incorporation and polymerase specificity (37), our primary goal in 
this study.   In addition, similar nucleotide selectivity for Klenow and DNA polymerase alpha 
has been demonstrated(38). Additionally, the quantitative variability of the enzyme system 
produces a relatively high degree of scatter, demonstrated in the relatively large standard 
deviation values (table 1). Thus the values of Km/V determined are reflective of a relative degree 
of enzyme activity within this assay, and useful for side-by-side comparison of and not a precise 
calculation of the Km/V.  
 
Zebularine was utilized as a cytosine analog (Figure 1A&D).  This is surprising given the 
absence of the NH2 group at the 4 position of the pyrimidine ring, which results in one less 
hydrogen bond for the G:Z pairing relative to the G:C pairing (Figures 3A and 4A).  Such a high 
degree of incorporation suggests effective recognition by the polymerase when bound to the 
primed template G.  This supports the role of zebularine as a demethylating agent and potential 
chemotherapeutic, because in order to block the activity of DNA methyltransferase, zebularine 
must first be specifically incorporated into DNA in place of cytosine (21, 39).  
 
We observed that zebularine has no significant incorporation opposite A.  Although the lack of a 
4-amino group on zebularine removes one repulsive force to mismatch pairing with A, there are 
no compatible hydrogen bond acceptors or donors to promote interaction with A (Figure 3B). 
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The only structural similarity to thymine or uracil is the absence of the 4-amino group (Figure 
1D, E&F), but the lack of a carbonyl group at the 4-position is apparently sufficient to 
distinguish Z from T and U and prevent any appreciable incorporation.  Similarly there is no 
significant incorporation opposite either thymine or cytosine, further supporting the hypothesis 
that dZTP is utilized efficiently in place of dCTP.  This result is significant since dZTP has 
previously been shown to be a weaker inhibitor of DNA methylation than 5-aza-dCTP(15).   One 
possible explanation, that dZTP is misincorporated in place of dTTP, thus mitigating its potency, 
is therefore excluded based on our observations.  
 
Although both dCTP and 5mdCTP are utilized effectively for incorporation opposite guanine and 
hypoxanthine , we observed a significant drop in the ability for dZTP to be used as a substrate 
when incorporated opposite hypoxanthine relative to dCTP and 5mdCTP (Table 1). This may be 
due to the decrease in hydrogen bonding sites in the hypoxanthine pairing relative to guanine.  
For both dCTP and 5mdCTP, there are three sites available for hydrogen bonding on guanine and 
two on hypoxanthine.  In the case of dZTP, the lack of a 4-amino group reduces the number of 
sites to one in pairing to hypoxanthine (Figure 3D).  Since a similar signal was observed for the 
incorporation of dCTP/d5mCTP opposite guanine and hypoxanthine, it seems a pairing with two 
hydrogen bond sites has a similar rate of incorporation to that of a pairing with three sites.  Thus 
the incorporation of dZTP opposite guanine occurs as readily as dCTP. However a drop to one 
available hydrogen bond (in the case of the Z-HX pairing) may decrease the stability of the 
complex and thus the rate of incorporation, explaining the reduced signal that we observed.  
Further studies using other modified pyrimidine base analogues would be necessary to confirm 
this hypothesis. 
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Z in the template strand behaves again as a C analog and most effective substrate utilization 
occurs with dGTP.  However, there is a low level of mispairing with dATP and to a lesser degree 
with dTTP.  This is consistent with earlier mutational studies.  A high rate of C to T mutations in 
Escherichia coli treated with zebularine may be the result of A:Z misincorporation during 
subsequent rounds of replication after dZTP has been incorporated into DNA (40).  Although 
when in the template strand Z prefers to pair with G, there is a significant decrease in nucleotide 
incorporation opposite Z.   This phenomenon is unique to Z and is not seen with C pairing 
opposite HX. Both Z:G and HX:C pairs include two hydrogen bonds compared to the three 
hydrogen bonds between C:G, and therefore, this chain termination is likely to be independent of 
the decreased hydrogen bonding between Z:G.   It has previously been reported that zebularine in 
the template strand leads to a direct block in DNA replication(41).  The effect of zebularine 
incorporation into the template deserves further study as this propensity for misincorporation and 
inhibition of DNA replication may eventually play a role in its chemotherapeutic effect. 
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Figure Captions 
 
Table 1: dNTP incorporation by Klenow fragment of DNA polymerase 1 opposite a variable 
template base in the sequence CTCAGTGTTACXGTACATGGGTTCCTATTG using the 
Pyrosequencer reaction.  Each value was determined through Lineweaver-Burke analysis of 
dNTP substrate concentration and Pyrosequencer peak height as a surrogate of reaction velocity 
Values are in s-1.  
 
Table 2: AMBER8 energies (kcal) for DNA duplexes containing zebularine. 
a Energies for duplex d(CTCAGTGTTANXGTACATGGGTTCCTATTG). 
d(CAATAGGAACCCATGTACY), containing an 11-base overhang, 5′-OH and 3′-OH ends, and 
47 sodium counterions included for neutrality.  
 
Figure 3: The structures are viewed from the minor groove of the DNA duplex, and the template 
strand is on the left in each structure. The C-Z, A-Z, G-Z and HX-Z pairs are identified, and the 
hydrogen bonds formed in the G-Z pair (two hydrogen bonds) and HX-Z pair (one hydrogen 
bond) are indicated by green dots. 
 
Figure 4: The structures are viewed from the minor groove of the DNA duplex, and the template 
strand is on the left in each structure. The Z-G, Z-A, Z-C and Z-T pairs are identified, and the 
hydrogen bonds formed in the Z-G pair (two hydrogen bonds), Z-A (one hydrogen bond), and Z-
T pair (one hydrogen bond) are indicated by green dots. 
 24
Table 1: Extrapolated Km/Vmax values (in s-1 units) calculated from Pyroseqencing by utilizing 
the signal intensity over a constant time interval as a surrogate for reaction velocity. 
 dCTP dGTP dTTP dZTP dUTP Ara-dCTP 5m-dCTP
A 
4.39X10-9 
 
+ 1.2X10-9 
1.74X10-9 
+1.41X10-10 
1.79X10-10 
+2.16X10-12 
1.24X10-8 
+1.61X10-9 
1.00X10-9 
+3.84X10-11 
1.64X10-8 
+3.90X10-10 
8.12X10-9 
+2.76X10-9
C 
3.30X10-9 
+8.50X10-10 
3.14X10-10 
+ 7.61X10-12 
4.25X10-9 
+2.55X10-10 
1.44X10-8 
+3.53X10-9 
1.38X10-8 
+3.33X10-9 
5.51X10-9 
+2.37X10-10 
6.50X10-9 
+1.10X10-9
G 
1.48X10-10 
+1.40X10-11 
1.84X10-8 
+1.25X10-8 
7.82X10-9 
+1.36X10-9 
2.09X10-9 
+2.21X10-10 
2.65X10-8 
+2.82X10-9 
1.99X10-10 
+1.81X10-9 
6.79X10-9 
+7.55X10-12
T 
1.37X10-9 
+8.00X10-10 
1.74X10-9 
+1.41X10-10 
1.10X10-8 
+3.21X10-9 
9.59X10-9 
+2.11X10-9 
2.92X10-8 
+7.62X10-9 
8.18X10-9 
+1.58X10-9 
8.59X10-9 
+1.94X10-10
I 
1.18X10-10 
+3.30X10-11 
2.12X10-9\ 
+1.58X10-10 
4.11X10-9 
+1.40X10-9 
3.46X10-9 
+1.04X10-9 
3.60X10-8 
+1.25X10-8 
2.30X10-10 
+2.29X10-9 
5.28X10-9 
+5.49X10-12
Z 
9.84X10-9 
+2.50X10-9 
2.19X10-10 
+9.84X10-13 
ND 2.93X10-8 
+ 3.27X10-9 
ND ND ND 
ND-Study not done 
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Table 2: AMBER8 energies for the DNA structures containing different base pairs 
 
X-Y a Energy X-Y a Energy 
C-G -861.8 I-C -846.8 
C-Z -842.4 I-Z -834.0 
A-T -848.4 Z-A -837.6 
A-Z -837.2 Z-T -839.8 
G-C -864.4 Z-C -839.4 
G-Z -846.4 Z-G -850.4 
 
N = C for X ≠ Z and N=G for X = Z.  
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Figure 1:  Structure of various nucleotide analogs.   
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R=ribose, deoxyribose, or deoxyribose triphosphate. (A) Cytosine,  (B) 5-Methylcytosine,  (C) 
Azacytosine  (if R=ribose then azacytidine; if R=deoxyribose then decitabine), (D) Zebularine,  
(E) Uracil,  and (F) Thymine 
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Figure 2: Schema showing the hybridized oligonucleotide template used in our Pyrosequencing 
assay. 
 
 
X=variable base (A, C, G, T, or Z). Incorporation of various nucleotide triphosphates, dNTP, 
was studied by Pyrosequencing.  
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Figure 3: Energy-minimized primer-template DNA structures following dZTP incorporation 
opposite (A) guanine, (B) adenine, (C) cytosine and (D) hypoxanthine. 
 
D
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Figure 4: Energy-minimized primer-template DNA structures following dNTP incorporation 
opposite zebularine. (A) dGTP, (B) dATP, (C) dCTP, and (D) dTTP. 
 
 
 
 
 
 
 
